Momolotinib is a kinase inhibitor targeted drug that was first approved by the US FDA in 2023, providing a new treatment option for adult anemia patients

1、 Drug name

1. Common name: Momelotinib

2. Product Name: OJJAARA

2、 Indications

Used to treat adult anemic patients with medium to high risk myelofibrosis (MF), including primary MF or secondary MF (after polycythemia vera and primary thrombocytosis).

3、 Specifications and characteristics

1. Specifications:

100mg。

2. Appearance: Thin film coated sheet.

4、 Main components

Active ingredient: Momelotinib Dihydrochloride monohydrate (chemical name see attachment).

5、 Usage and dosage

1. Recommended dosage: 200mg orally, once daily, before or after meals.

2. Swallow the whole piece, do not cut, chew or crush it.

3. Omission treatment: If missed, take according to the original plan the next day without the need for supplementation.

6、 Dose adjustment

1. Liver dysfunction:

Severe liver injury (Child Pugh C grade): The initial dose is reduced to 150mg/day.

2. Adverse reaction adjustment (based on indicators such as platelets and neutrophils):

When there is a decrease in platelets or neutrophils, it needs to be interrupted or reduced (see the attached table for details).

7、 Medication precautions

1. Dietary influence: not affected by food.

2. Vomiting treatment: If vomiting occurs after taking medication, there is no need to take additional medication, and medication should be taken the next day according to the plan.

3. Monitoring requirements:

Regular blood routine and liver function tests should be conducted before and during medication.

Be alert to symptoms such as infection, bleeding, and blood clots.

8、 Medication for special populations

1. Pregnant women: May cause fetal damage, use only when benefits outweigh risks.

2. Breastfeeding period: Do not breastfeed for at least one week after discontinuing medication.

3. Elderly: No need to adjust dosage.

9、 Adverse reactions

1. Common (≥ 20%): thrombocytopenia, bleeding, bacterial infection, fatigue, dizziness, diarrhea, nausea.

2. Serious risks: infection, hepatotoxicity, cardiovascular events, malignant tumors (especially in smokers).

10、 Contraindications

There are no absolute contraindications, but patients with active infections need to delay medication.

11、 Drug interactions

1. OATP1B1/B3 inhibitors (such as rifampicin): may increase exposure to Molotinib and require monitoring for adverse reactions.

2. BCRP substrates (such as rosuvastatin): dosage adjustment is required (rosuvastatin is limited to 5-10mg/day).

12、 Storage method

Not explicitly stated, it is recommended to follow the conventional oral medication storage (avoid light, dry, below 25 ℃).

Momelotinibinformation